×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RVNC – revance therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RVNC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/11
07:25 am
rvnc
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
Medium
Report
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
11/10
11:00 am
rvnc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
High
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
11/10
02:03 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/8
01:44 pm
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/8
12:00 pm
rvnc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
Neutral
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
11/8
11:37 am
rvnc
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.60 price target on the stock.
Low
Report
Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.60 price target on the stock.
11/8
10:45 am
rvnc
Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC
Medium
Report
Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC
11/8
07:30 am
rvnc
Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud Allegations
High
Report
Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud Allegations
Date
Time
Symbol
Company Name
Action
%Chg
8/8/2024
04:05 pm
RVNC
revance therapeutics, inc.
BEAT
Report
19.7%
revance therapeutics, inc.
5/9/2024
04:06 pm
RVNC
revance therapeutics, inc.
BEAT
Report
-22.6%
revance therapeutics, inc.
2/28/2024
04:05 pm
RVNC
revance therapeutics, inc.
BEAT
Report
26.1%
revance therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:32 am
rvnc
Form 8-K Revance Therapeutics, For: Nov 12
Medium
Report
Form 8-K Revance Therapeutics, For: Nov 12
11/7
04:23 pm
rvnc
Form 10-Q Revance Therapeutics, For: Sep 30
High
Report
Form 10-Q Revance Therapeutics, For: Sep 30
11/7
04:14 pm
rvnc
Form 8-K Revance Therapeutics, For: Nov 07
High
Report
Form 8-K Revance Therapeutics, For: Nov 07
11/1
09:25 am
rvnc
Form 8-K Revance Therapeutics, For: Nov 01
Low
Report
Form 8-K Revance Therapeutics, For: Nov 01
10/31
01:20 pm
rvnc
Form SCHEDULE 13G/A Revance Therapeutics, Filed by: FRANKLIN RESOURCES INC
Low
Report
Form SCHEDULE 13G/A Revance Therapeutics, Filed by: FRANKLIN RESOURCES INC
10/28
06:02 am
rvnc
Form 8-K Revance Therapeutics, For: Oct 24
High
Report
Form 8-K Revance Therapeutics, For: Oct 24
10/23
07:17 pm
rvnc
Form SC 13G/A Revance Therapeutics, Filed by: GIC Private Ltd
Low
Report
Form SC 13G/A Revance Therapeutics, Filed by: GIC Private Ltd
10/18
09:29 am
rvnc
Form 8-K Revance Therapeutics, For: Oct 18
Low
Report
Form 8-K Revance Therapeutics, For: Oct 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
18.3%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
5/9 Revance Therapeutics, Inc. (RVNC) on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 16.5%
10/14 Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne 15.1%
4/2 Revance Therapeutics Inc (NASDAQ: RVNC) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.4%
12/2 Revance Therapeutics Inc (NASDAQ: RVNC) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $25.00 price target on the stock. 8.2%
1/11 Did Changing Sentiment Drive Revance Therapeutics's (NASDAQ:RVNC) Share Price Down By 25%? [Yahoo! Finance News] 7.7%
8/8 Revance Therapeutics Inc (NASDAQ: RVNC) had its "outperform" rating re-affirmed by analysts at William Blair. 7.2%
1/15 Revance Therapeutics Inc (NASDAQ: RVNC) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $24.00 price target on the stock. 5.3%
10/15 Form 8-K Revance Therapeutics, For: Oct 11 4.7%
7/29 Revance to Release Second Quarter 2019 Financial Results on Monday, August 5, 2019 4.6%
TOP News Decliners
4/1
Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $35.00 price target on the stock.
-14.9%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
12/3 Revance Announces Proposed Public Offering of Common Stock -14.6%
3/17 Form 4 Revance Therapeutics, For: Mar 15 Filed by: Joshi Abhay -13.7%
3/13 Form SC 13G Revance Therapeutics, Filed by: GIC Private Ltd -12.0%
2/25 Revance Therapeutics Inc (NASDAQ: RVNC) had its price target raised by analysts at Needham & Company LLC from $32.00 to $36.00. They now have a "buy" rating on the stock. -9.6%
2/10 Form 8-K Revance Therapeutics, For: Feb 10 -9.2%
4/15 Revance Therapeutics Inc (NASDAQ: RVNC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $36.00 price target on the stock. -7.3%
2/26 Form 10-K Revance Therapeutics, For: Dec 31 -7.2%
4/30 Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020 -6.5%
8/27 Form 8-K Revance Therapeutics, For: Aug 22 -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: